Transform Possibilities Into Breakthroughs, Because Every Moment Matters
Browse our posters from Oligonucleotide Therapy Society (OTS) 2025 and learn how we can support your ASO therapeutic development by using an integrated approach that includes selecting the best mechanism for gene target, the right species, ASO design and screening, formulation, delivery, biodistribution, efficacy, toxicology, IND safety assessment. and regulatory guidance.
Want to speak with one of our experts from OTS 2025?
| Electrophoretic Mobility Shift Assay (EMSA) for the Analysis of Protein Binding of Oligonucleotides and siRNA | Zoltan Timar, Research Scientist |
| Factors for Consideration in the Evaluation Plan for the Anti-Drug Antibody Immune Response to Oligonucleotide Treatments | Lisa Walker, Research Scientist |
| Enhancing Antisense Oligonucleotide Therapeutics Development for Individuals through Industry-Academia Collaborations | Roxana Redis, Science Director, in collaboration with Marlen Laufer, Dutch Center for RNA Therapeutics |
| Preclinical Toxicology and Biodistribution Evaluation of Antisense Oligonucleotides (ASOs) | Mariette Heins, Director |
| Therapeutics Development for a Patient with a KCNQ3/ Kv7.3 Disorder using an iPSC-based Platform Measuring Neural Network Activity | Dario Magnani, Senior Research Leader |
| Therapeutics Development for Dup15q Syndrome using an iPSC-based Platform Measuring Neural Network Activity | Dario Magnani, Senior Research Leader |
Giacomo Mancini, PhD
Associate Director, Client Services